Aliskiren , ≥98% , 173334-57-1

Synonym(s):
(2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide

CAS NO.：173334-57-1

Empirical Formula: C30H53N3O6

Molecular Weight: 551.76

MDL number: MFCD09839018

EINECS: 605-672-4

PRODUCT Properties

• Melting point: 98-99 °C
• Boiling point: 748.4±60.0 °C(Predicted)
• Density: 1.067±0.06 g/cm3(Predicted)
• storage temp.: Inert atmosphere,Store in freezer, under -20°C
• solubility: DMSO : 100 mg/mL (181.24 mM; Need ultrasonic)
• form: Powder
• pka: 9.49(at 25℃)
• color: White to light yellow

Description and Uses

Aliskiren is a first-in-class antihypertensive drug that acts by direct inhibition of renin. It is indicated for oral administration either as monotherapy or in combination with other antihypertensive agents. Renin catalyzes the cleavage of angiotensin to form angiotensin I, the first and the rate-limiting step of the RAAS. The inhibition of renin by aliskiren results in reduced levels of angiotensin I, angiotensin II, and aldosterone, all of which contribute to the antihypertensive effect. RAAS modulators are among some of the most commonly prescribed antihypertensive agents to date.The most common side effect of aliskiren is diarrhea, particularly with doses higher than 300mg daily. Unlike ACE inhibition, direct inhibition of renin does not increase bradykinin levels. Elevated bradykinin levels are thought to be responsible for the angioderma and cough that occur commonly during treatment with ACE inhibitors. .

An orally active, synthetic nonpeptide renin inhibitor. Antihypertensive

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319-H335
• Precautionary statements: P261-P264-P271-P280-P302+P352-P305+P351+P338